Stem Cell Therapy and Treatments — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stem cell therapy encompasses a broad and rapidly evolving category of medical treatments that use stem cells — undifferentiated cells capable of self-renewal and differentiation into specialised cell types — to repair, replace, or regenerate diseased or damaged tissues. The field spans from well-established haematopoietic stem cell transplantation (HSCT), practised clinically since the 1960s, to cutting-edge chimeric antigen receptor T-cell (CAR-T) immunotherapies and gene-corrected stem cell products approved within the past decade.

The three principal stem cell categories used therapeutically are: haematopoietic stem cells (HSCs), which give rise to all blood and immune cells; mesenchymal stem/stromal cells (MSCs), found in bone marrow, adipose tissue, and umbilical cord, with immunomodulatory and tissue-repair properties; and induced pluripotent stem cells (iPSCs), adult cells reprogrammed to an embryonic-like state (Yamanaka 2006, Nobel Prize 2012), enabling patient-specific cell therapies without ethical concerns of embryonic stem cells.

A critical distinction in this field is between FDA/EMA-approved stem cell therapies — which have undergone rigorous phase III clinical trials demonstrating safety and efficacy — and unproven treatments offered by unregulated clinics, which may pose serious or life-threatening risks. The FDA has issued numerous warning letters and pursued criminal enforcement actions against clinics offering unproven stem cell injections for conditions ranging from autism to ALS, with serious adverse events including blindness, infections, and tumour formation documented in post-marketing surveillance data published through 2024.

Patients considering any stem cell-based intervention should consult ISSCR (International Society for Stem Cell Research) patient resources and verify that any proposed treatment has either regulatory approval or is conducted under an approved clinical trial (ClinicalTrials.gov).

The scope of conditions with approved or strong evidence-based stem cell treatments is more limited than often portrayed in media. The following represents the evidence-graded landscape as of 2024:

• Haematological malignancies (highest evidence — standard of care): Acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), myelodysplastic syndrome (MDS), chronic myeloid leukaemia (CML), and chronic lymphocytic leukaemia (CLL) are treated with HSCT — the most established stem cell therapy globally.
• Haematological non-malignant conditions: Aplastic anaemia, sickle cell disease, thalassaemia, Fanconi anaemia, severe combined immunodeficiency (SCID), and other primary immunodeficiency disorders benefit from allogeneic HSCT as curative or definitive therapy.
• CAR-T eligible diseases: Relapsed/refractory large B-cell lymphoma (axicabtagene ciloleucel, lisocabtagene maraleucel), B-cell ALL in children and young adults (tisagenlecleucel), multiple myeloma (ciltacabtagene autoleucel, idecabtagene vicleucel), mantle cell lymphoma (brexucabtagene autoleucel), and follicular lymphoma (axicabtagene and tisagenlecleucel — FDA approvals 2021–2024).
• Genetic diseases treated with gene-corrected stem cells: ADA-SCID (Strimvelis — EMA approved, ex vivo gene therapy using HSCs); beta-thalassaemia (Zynteglo/betibeglogene — FDA 2022, EMA 2019); cerebral adrenoleukodystrophy — CALD (Skysona/elivaldogene — FDA 2022, for boys aged 4–17).
• Autoimmune diseases (investigational/selected cases): Severe treatment-refractory multiple sclerosis (autologous HSCT — MIST trial, 2019), systemic sclerosis, systemic lupus erythematosus, and Crohn disease (MSC therapy — remestemcel-L, EMA approved for paediatric steroid-refractory acute GvHD).
• Ophthalmology (iPSC clinical trials): Macular degeneration (subretinal RPE cell transplantation using iPSC-derived cells — phase I/II trials in Japan and internationally).

Eligibility for stem cell therapies depends critically on the specific product, the patient's diagnosis, prior treatment history, and overall health status.

• HSCT eligibility: Requires a confirmed indication (haematological malignancy or severe non-malignant blood disorder), adequate performance status (ECOG 0–2 for myeloablative conditioning; ECOG 0–3 for reduced-intensity), adequate organ function (cardiac, pulmonary, hepatic, renal), and, for allogeneic HSCT, availability of a suitable donor (matched sibling, 10/10 matched unrelated, haploidentical, or cord blood).
• CAR-T eligibility: Each CAR-T product has a specific approved indication. For example, axicabtagene (Yescarta) for LBCL requires ≥2 prior lines of therapy including anti-CD20 and anthracycline. Patients must have adequate cardiac function (LVEF ≥50%), no active CNS lymphoma involvement (for most indications), and access to a REMS-certified treatment centre due to the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Age and performance status: Most CAR-T products are approved for adults; tisagenlecleucel is approved for patients up to age 25 for ALL. Strimvelis is approved for ADA-SCID without a matched sibling donor, at any age. Skysona is licensed only for boys aged 4–17 with early-stage CALD.
• Donor matching: Allogeneic HSCT outcomes are optimised with 10/10 HLA-matched unrelated donors (MUD). Haploidentical (half-matched, typically a parent or sibling) transplantation using post-transplant cyclophosphamide (PT-Cy) has expanded access to patients without matched donors.
• Exclusion criteria: Active uncontrolled infection, severe organ dysfunction, prior allogeneic HSCT (relative contraindication for some CAR-T products), active autoimmune disease requiring systemic immunosuppression, and pregnancy generally preclude eligibility for most stem cell treatments.

Only stem cell therapies that have received regulatory approval from the FDA or EMA should be considered established treatments. The major approved categories are:

• CAR-T Cell Therapies (FDA-approved):
  • Axicabtagene ciloleucel (Yescarta, Kite/Gilead): Anti-CD19 CAR-T; approved for relapsed/refractory LBCL, follicular lymphoma, and as second-line therapy for LBCL (ZUMA-7 trial, 2022).
  • Tisagenlecleucel (Kymriah, Novartis): Anti-CD19 CAR-T; approved for paediatric/young adult B-cell ALL (ELIANA trial) and relapsed/refractory LBCL (JULIET trial).
  • Ciltacabtagene autoleucel (Carvykti, Janssen/Legend): Anti-BCMA CAR-T; approved for relapsed/refractory multiple myeloma after ≥4 prior lines (CARTITUDE-1 trial, 2022); expanded to earlier-line use in 2024.
  • Lisocabtagene maraleucel (Breyanzi, BMS): Anti-CD19 CAR-T with defined CD4:CD8 ratio; approved for LBCL and, in 2023, for relapsed/refractory CLL/SLL (TRANSCEND CLL 004 trial).
  • Brexucabtagene autoleucel (Tecartus, Kite): Anti-CD19 CAR-T; approved for mantle cell lymphoma and relapsed/refractory B-cell ALL in adults.
  • Idecabtagene vicleucel (Abecma, BMS/2seventy bio): Anti-BCMA CAR-T; approved for relapsed/refractory multiple myeloma.
• Gene-Corrected Stem Cell Products:
  • Strimvelis (GSK, EMA 2016): Ex vivo gene therapy using autologous CD34+ HSCs corrected with a gamma-retroviral vector for ADA-SCID. Single administration provides sustained immune reconstitution.
  • Zynteglo / betibeglogene spartacel (bluebird bio, FDA 2022): Lentiviral vector-corrected autologous HSCs for transfusion-dependent beta-thalassaemia; clinical trials demonstrated transfusion independence in the majority of treated patients.
  • Skysona / elivaldogene autotemcel (bluebird bio, FDA 2022): Lentiviral-corrected HSCs for early-stage cerebral adrenoleukodystrophy (CALD) in boys 4–17 years; slows progression of neurological dysfunction.
• Conventional HSCT: Remains the backbone for haematological malignancies and bone marrow failure syndromes. Autologous HSCT (patient's own stem cells, collected and reinfused after high-dose chemotherapy) and allogeneic HSCT (donor stem cells, providing a graft-versus-tumour effect) are described in detail in the Stem Cell Transplantation page.
• MSC-based therapies: Remestemcel-L (Prochymal/Ryoncil) is approved in several countries for steroid-refractory acute GvHD in children. Other MSC products are under investigation for osteoarthritis, Crohn disease, and cardiac repair but remain experimental pending phase III evidence.

Approved stem cell therapies offer transformative outcomes in diseases that were previously incurable or had very poor prognoses.

• CAR-T in haematological malignancies: In patients with relapsed/refractory LBCL — a disease with historically dismal prognosis — axicabtagene ciloleucel produces complete response rates of 54% in the ZUMA-1 trial, with durable remissions in approximately one-third of patients at 5 years. In the ZUMA-7 second-line trial, CAR-T demonstrated superior event-free survival over autologous HSCT as second-line salvage.
• Curative potential for genetic diseases: Strimvelis achieves immune reconstitution in the majority of ADA-SCID patients, effectively curing a condition that was previously fatal without a matched sibling donor. Zynteglo provides transfusion independence in approximately 89% of non-beta-0/beta-0 beta-thalassaemia patients (HGB-207 trial).
• HSCT in leukaemia: Allogeneic HSCT provides cure rates of 40–60% in standard-risk AML in first complete remission and 60–70% in ALL in first remission with appropriate donor selection.
• Multiple myeloma outcomes: Autologous HSCT followed by maintenance lenalidomide is associated with a median progression-free survival of 54 months (IFM 2009 trial). CAR-T products targeting BCMA (Carvykti, Abecma) produce overall response rates of 73–98% in heavily pre-treated myeloma, with complete response rates of 39–82%.
• Quality of life: Patients achieving durable remission with CAR-T or HSCT report substantial quality-of-life improvement. Those with cured genetic diseases such as ADA-SCID or beta-thalassaemia are freed from lifelong transfusion dependency or enzyme replacement therapy.

Stem cell therapies, even when properly administered, carry significant risks. Unregulated treatments add an additional layer of serious danger.

• Cytokine Release Syndrome (CRS): The most common serious toxicity of CAR-T therapy, occurring in 70–90% of patients to some degree. Severe CRS (grade 3–4) occurs in 10–30%. Manifestations include high fever, hypotension, hypoxia, and multi-organ dysfunction. Managed with tocilizumab (anti-IL-6 receptor) and corticosteroids per ASTCT grading criteria.
• Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS): Occurs in 20–60% of CAR-T recipients; ranges from confusion and aphasia to seizures and cerebral oedema. Managed with dexamethasone. Generally reversible but can be life-threatening.
• Graft-versus-Host Disease (GvHD): A major complication of allogeneic HSCT where donor T-cells attack host tissues. Acute GvHD (grades II–IV) occurs in 30–50% of matched unrelated donor transplants; chronic GvHD affects 30–70% of long-term survivors. Can affect skin, gut, liver, lungs, and musculoskeletal system. Details covered in the Stem Cell Transplantation guide.
• Infections: Prolonged immunosuppression after HSCT creates vulnerability to bacterial, fungal (Aspergillus, Candida), and viral (CMV, EBV, adenovirus) infections during the engraftment period and beyond.
• Insertional mutagenesis: A theoretical and historically documented risk of gamma-retroviral gene therapy vectors (e.g., early ADA-SCID trials). Modern lentiviral vectors have a substantially lower risk profile, but long-term follow-up monitoring is required for all gene therapy recipients.
• Unregulated clinic dangers: A 2019 NEJM investigation documented 35 serious adverse events including blindness, infections, and tumour formation in patients who received unproven adipose-derived stem cell injections from unregulated US clinics. The FDA escalated enforcement in 2024, including criminal referrals and permanent injunctions against clinics offering unproven IV stem cell infusions for neurological conditions, autism, and orthopaedic conditions. Patients should verify any stem cell treatment at ClinicalTrials.gov, access the ISSCR Patient Handbook, and seek care only at accredited transplant centres.

Post-treatment monitoring is intensive and ongoing, reflecting the complexity of these therapies and the need for early detection of complications.

• CAR-T follow-up: After CAR-T infusion, patients are monitored inpatient or in outpatient settings with REMS-certified staff for a minimum of 7–14 days due to the risk of delayed CRS and ICANS. Specific neurological assessments (ICANS scoring) and vital sign monitoring are performed at least twice daily during this period. Subsequent outpatient follow-up includes complete blood counts, metabolic panels, and inflammatory markers weekly for the first month, then monthly.
• CAR-T persistence and response: Response is assessed at 1, 3, and 6 months by PET-CT or bone marrow biopsy as appropriate to the underlying malignancy. CAR-T cell persistence (measured by flow cytometry or PCR) correlates with durability of response and is monitored at major academic centres.
• Gene therapy follow-up: Patients treated with Strimvelis, Zynteglo, or Skysona are enrolled in long-term follow-up studies for 15 years post-treatment, as required by regulatory agencies. This includes annual monitoring for insertional oncogenesis, immune reconstitution, and vector copy number.
• HSCT long-term follow-up: Detailed in the Stem Cell Transplantation section. Key elements include GvHD surveillance, infection prophylaxis, immune reconstitution monitoring, and screening for late effects (secondary malignancies, cardiac and pulmonary toxicity, endocrine dysfunction, avascular necrosis).
• Hypogammaglobulinaemia: A common long-term consequence of CD19-directed CAR-T therapy (B-cell aplasia). Many patients require monthly intravenous immunoglobulin (IVIG) replacement for months to years after treatment to prevent serious bacterial infections.

Stem cell therapies, particularly CAR-T products and gene therapies, are among the most expensive medical treatments in history. Understanding cost drivers is essential for patients, families, and payers.

• CAR-T therapy list prices (US, 2024): Yescarta (axicabtagene) approximately USD 373,000 per infusion; Kymriah (tisagenlecleucel) approximately USD 475,000 for ALL and USD 343,000 for LBCL; Carvykti (ciltacabtagene) approximately USD 465,000; Breyanzi (lisocabtagene) approximately USD 410,300. These prices do not include hospitalisation, management of toxicities, or required monitoring.
• Gene therapy prices: Zynteglo (betibeglogene) is priced at USD 2.8 million per treatment — one of the highest-priced therapies ever approved. Skysona is priced at USD 3 million. These are designed as one-time curative treatments, and outcomes-based payment models are being developed.
• HSCT costs: Autologous HSCT in the US costs USD 150,000–350,000 including conditioning, the transplant, and the initial hospitalisation. Allogeneic HSCT typically costs USD 300,000–800,000 or more depending on conditioning intensity, donor type (matched unrelated is more expensive than sibling), and complications.
• International cost variation: HSCT costs in India range from USD 25,000–60,000; in Thailand, USD 40,000–80,000; in Germany and Singapore, USD 150,000–400,000. India is emerging as a significant medical tourism destination for affordable HSCT.
• Insurance and access: In the US, CAR-T therapy is generally covered by Medicare and many commercial insurers for approved indications following completion of prior required therapy lines. European countries vary; many provide HSCT through national health systems but CAR-T access depends on health technology assessment (NICE, G-BA) decisions. Manufacturer patient assistance programmes may be available for uninsured patients.
• Clinical trials: Patients enrolled in approved clinical trials for stem cell therapies typically receive the investigational treatment at no cost, though ancillary care expenses may not be covered.

For many conditions where stem cell therapy is used, alternative treatments exist — some as bridges to transplant, others as definitive alternatives for patients who are ineligible or prefer to avoid the associated risks.

• Conventional chemotherapy and immunotherapy: For haematological malignancies, multi-drug chemotherapy regimens (CHOP, DHAP, R-CHOP, VRd, etc.) remain first-line treatments. Bispecific antibodies (blinatumomab for ALL; epcoritamab, glofitamab for LBCL; teclistamab for myeloma) are emerging as CAR-T alternatives with off-the-shelf availability and more manageable toxicity profiles.
• Targeted therapy: BCR-ABL inhibitors (imatinib, dasatinib, ponatinib) have transformed CML management, largely replacing allogeneic HSCT as first-line therapy. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are active in CLL and MCL without transplant. Venetoclax combinations in AML achieve high CR rates in elderly patients not eligible for HSCT.
• Enzyme replacement therapy (ERT): For ADA-SCID, PEG-ADA (pegademase bovine) enzyme replacement maintains immune function but requires lifelong injections and provides inferior immune reconstitution compared to Strimvelis gene therapy or HSCT. For beta-thalassaemia, luspatercept (Reblozyl) reduces transfusion burden and may be an alternative or complement to Zynteglo gene therapy.
• Allogeneic HSCT as alternative to CAR-T: In some settings, allogeneic HSCT with or without donor lymphocyte infusions remains a viable option for patients with relapsed disease not eligible for CAR-T. The ZUMA-7 trial data suggest CAR-T is superior to auto-HSCT as second-line salvage for eligible LBCL patients.
• Watchful waiting and supportive care: In indolent lymphomas and low-risk MDS, active surveillance may be appropriate. Supportive care measures (transfusions, growth factors, infection prophylaxis) can maintain quality of life without aggressive intervention in frail or elderly patients.

Patients should discuss all available options including clinical trial participation with their haematologist or oncologist at a centre experienced in both conventional and cellular therapies.